Compare Humana Inc (HUM) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Impinj Inc — how do they compare? Humana Inc trades at $405.62 (market cap $47.81B), while Impinj Inc trades at $136.46 (market cap $4.19B). The key difference: Humana Inc is far larger — about 11.4× Impinj Inc's market cap, and Humana Inc pays a 0.89% dividend while Impinj Inc pays none. Which is the better fit depends on your goals.
| HUM | PI | |
|---|---|---|
Market Cap | $47.81B | $4.19B |
Sector | Health | Technology |
52-Week High | $409.42 | $241.91 |
52-Week Low | $163.67 | $91.34 |
Enterprise Value | $56.85B | $4.33B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
Impinj (PI) trades at $137.72, down 0.33% on the day, with a bearish technical signal from moving averages despite recent earnings beats. The company reported Q1 2026 EPS of $0.14, exceeding expectations, but maintains negative net income margins and high valuation multiples. Recent insider sales and mixed news flow highlight investor caution amid specialized RFID market positioning.
PI offers growth potential in RFID technology with strong analyst buy ratings (72.7% consensus) and a $167.50 price target, but faces significant risks from profitability challenges, high debt-to-asset ratio (51.52% in 2025), and competitive pressures. The stock's outlook hinges on execution improvement and market expansion to justify current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
